Sharemaestro Newsreel

Sera Prognostics Reports Q2 Revenue of $30000 and $9.1 Million Net Loss

Sera Prognostics Q2 2026 Earnings: Commercial Progress Has Yet to Produce Material Revenue

Sera Prognostics (SERA) deepens Q2 2026 loss but extends cash runway to 2029

Lucid Diagnostics 2026: Revenue $1.47M, EPS ($0.08) — 10-Q Summary

Lucid Diagnostics Inc. reported its Q2 2026 financial results, showing revenue of $1.47 million and a net loss of ($14.72 million), resulting in a diluted loss per share of ($0.08). The company experienced increased EsoGuard test volume, expanded commercialization efforts, secured positive payer access …

Nexalin Technology | 8-K: Current report

This article is a current report (8-K) filed by Nexalin Technology. It signifies a significant event that the company is required to disclose to the SEC, though the specific details of the event are not provided in this snippet.

Nortech Systems' Total Backlog Rises 20% to $93.8M in Q2

Nortech Systems (Nasdaq:NSYS) reported solid Q2 2026 financial results, with net sales increasing 9.3% to $33.5 million and net income remaining largely flat at $316 thousand. The company's total backlog grew 20% year-over-year to $93.8 million, indicating strong future business prospects, particularly in Aerospace …

Nortech Systems (NSYS) swings to profit as sales and backlog rise in 2026

Nortech Systems (NSYS) reported a significant financial turnaround for the first half of 2026, swinging to a net profit of $0.3 million from a $1.0 million loss a year prior. This improvement was driven by a 10.9% increase in net sales to $63.9 million, …

IceCure Medical Q2 2026 Earnings Call Transcript

IceCure Medical reported a 45% year-over-year revenue increase to $1.8 million for the first half of 2026, driven by higher ProSense system sales and disposable probe utilization. The company's U.S. commercial install base grew by 70% to over 30 sites following FDA clearance for …

MaxCyte Reports Second Quarter 2026 Financial Results

MaxCyte, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting total revenue of $7.3 million, a 15% decrease year-over-year, and a net loss of $8.9 million, an improvement from the $12.4 million loss in Q2 2025. The company reiterated …

Nortech Systems Reports Second Quarter Results

Earnings Flash (LMRI) Lumexa Imaging Holdings, Inc. Reports Q2 Revenue $264.2M, vs. FactSet Est of $263.1M

Lumexa Imaging Holdings, Inc. (LMRI) announced its Q2 revenue of $264.2 million, surpassing FactSet's estimate of $263.1 million. The company also reiterated its full-year 2026 revenue guidance, projecting a range of $1.045 billion to $1.097 billion against an estimate of $1.066 billion. Lumexa Imaging …

Lumexa Imaging Announces Second Quarter 2026 Results

Lumexa Imaging (Nasdaq: LMRI) reported strong second-quarter 2026 results, showing a 5.1% increase in consolidated revenues to $264.2 million and a net income of $2.7 million. The company also updated its full-year 2026 outlook, reiterating revenue guidance and narrowing its Adjusted EBITDA range, reflecting …

QT Imaging Holdings (QTI) doubles revenue but takes $8.3M debt loss in Q2 2026

Boston Scientific (BSX) SVP Emily Woodworth adds 2,930 shares in 401(k) rebalance

Emily Woodworth, SVP, Global Controller and CAO at Boston Scientific (BSX), acquired 2,930 shares of common stock at $51.19 per share through a 401(k) rebalance on August 11, 2026. This transaction increased her indirect 401(k) holdings to 2,930 shares, in addition to her 3,123 …

STERIS plc SEC Filing (Aug 12, 2026)

This article reports on an SEC Form 144 filing by STERIS plc (STE) on August 12, 2026, detailing a proposed sale of 4058 shares of ordinary stock by an individual through an employee stock option exercise. The filing, which has a neutral impact and …

Abbott Laboratories stock outperforms competitors on strong trading day

Shares of Abbott Laboratories (ABT) rose 1.08% to $110.91, marking its third consecutive day of gains. This performance occurred on a mixed trading day where the S&P 500 Index increased by 0.26% and the Dow Jones Industrial Average fell by 0.04%. The stock's positive …

QT Imaging Ships 28 Breast Scanners, Expands U.S. Sales Team

Sera Prognostics Analysis Shows 22% Fewer NICU Admissions

Insulet hires Pfizer alum Joan Campion to lead external comms

Insulet, a medical device company, has appointed Joan Campion, formerly of Pfizer, as its new VP of external communications for corporate affairs. This new role is part of a broader effort by Insulet to enhance its communications function under Chief Corporate Affairs Officer Cristal …

Senseonics Holdings, Inc. - Common Stock (Nasdaq:SENS) Stock Quote

CeriBell (NASDAQ:CBLL) Trading Up 9.7% - Here's Why

CeriBell (NASDAQ:CBLL) saw its stock price jump by 9.7% to $23.37 following bullish analyst actions from Canaccord Genuity and BTIG Research, despite missing earnings estimates. The company, which specializes in newborn hearing screening devices, still faces unprofitability with a negative net margin, and insiders …

BrainsWay (BWAY) shows 35% revenue growth, 75% gross margin and rising backlog

BrainsWay Ltd. (BWAY) reported a strong Q2 2026, with 35% revenue growth, a 75% gross margin, and a 314% increase in operating income, driven by its Deep TMS interventional psychiatry platform. The company shipped 125 systems, expanded its installed base to 1,950 worldwide, and …

QT Imaging Holdings (QTI) doubles Q2 revenue but books $11.1M net loss

QT Imaging Holdings reported a 103% increase in Q2 revenue to $7.4 million, driven by increased shipments of Breast Acoustic CT scanners. Despite this growth and reaffirmed 2026 revenue guidance of $39 million, the company posted an $11.1 million net loss, largely due to …

AQR Capital discloses 5.39% Outset Medical (OM) ownership in Schedule 13G

AQR Capital Management Holdings, LLC and its subsidiary AQR Capital Management, LLC have disclosed a 5.39% beneficial ownership in Outset Medical, Inc. (OM), according to a Schedule 13G filing. The entities collectively own 998,961 shares of common stock, demonstrating shared voting power over 966,795 …

Artivion (AORT) Is Up 5.5% After FDA AMDS Approval And Reaffirmed 2026 Revenue Guidance - What's Changed

Artivion (AORT) stock rose by 5.5% following FDA approval for its AMDS hybrid prosthesis and the reaffirmation of its 2026 revenue guidance. The company reported increased revenue but a shift to a net loss in Q2 2026. This approval for AMDS is considered a …

908 Devices: Mission Critical Devices Drive Growth (NASDAQ:MASS)

Mobia Medical Q2 Loss Narrows, Revenue Rises

Mobia Medical reported a narrowed net loss and increased revenue for its second quarter. The company's net loss decreased to $0.4 million from $1.1 million in the prior year, while revenue grew by 15% to $4.6 million due to strong performance in its medical …

NeuroPace Q2 Earnings Call Highlights

NeuroPace reported strong Q2 revenue growth driven by its RNS System for adult focal epilepsy, leading to a raised full-year revenue and adjusted EBITDA outlook. The company is also engaging with the FDA regarding expanding the RNS System's indication to idiopathic generalized epilepsy (IGE), …

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, …

DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?

DexCom DXCM stock has rebounded sharply in 2026, gaining 34.8% after falling 14.7% in 2025, as investors increasingly recognize the company's improving growth profile and expanding continuous glucose monitoring (CGM) opportunity. The company's share price performance so far this year has outperformed the industry's …

ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?

Intuitive Surgical ISRG has faced a moderation in U.S. procedure growth during the first half of 2026, but management's commentary suggests the slowdown is more likely a temporary demand-timing issue than evidence of a structural deterioration. U.S. da Vinci procedures grew 12% in the …

Teledyne Technologies (TDY) Agrees $1.1 Billion Imaging Deal To Deepen X Ray Reach

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Teledyne Technologies (NYSE: TDY) agreed to acquire Varex Imaging for US$1.1b, expanding its X ray and CT detector portfolio. The deal adds photon …

SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales

Jeremy Hayden, an insider at Sight Sciences, Inc. (SGHT), has filed a Form 144 detailing planned sales of common stock through Fidelity Brokerage Services LLC. The filing also reports prior restricted stock vestings from January 2024, March 2024, and a scheduled vesting in January …

Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?

DexCom (DXCM) has raised its 2026 revenue and margin outlook following a strong second quarter, shifting focus towards profitability. The company's G7 15 Day rollout is contributing to improved gross margins and manufacturing efficiency. Despite the positive outlook, potential foreign exchange headwinds, manufacturing investments, …

DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?

DexCom (DXCM) shares have surged 52.5% in the last three months, outperforming major benchmarks, driven by strong Q2 2026 earnings and improved margins. While the company's fundamental performance is robust with revenue growth and margin expansion, its premium valuation necessitates consistent execution to justify …

Insulet (PODD) Q2 2026 Earnings Call Transcript

Insulet reported strong Q2 2026 results with 23% revenue growth and increased profitability, driven by demand for Omnipod. However, the company lowered its full-year revenue outlook due to lower-than-anticipated retention and utilization rates among Type 2 diabetes customers, particularly in the initial 90 days …